Stocks to Watch: Adobe, Champions Oncology, DBV Technologies

Dow Jones2024-12-12

By Connor Hart

Adobe's fiscal 2025 outlook missed estimates. The software maker expects revenue between $23.3 billion and $23.55 billion for the current fiscal year, missing the $23.78 billion that analysts polled by FactSet expect. It also guided for adjusted per-share earnings between $20.20 and $20.50, compared with the $20.52 for which analysts are looking. The company's lower-than-expected outlook came as it posted higher revenue and earnings in its fiscal 4Q. Shares slide 8.8%, to $501.55, in after-hours trading.

Champions Oncology swung to a profit and reported higher revenue in the latest quarter due to bookings growth and operational improvements. The technology-enabled research company posted earnings of 5 cents a share on revenue of $13.5 million, compared with a loss of 15 cents a share on revenue of $11.6 million a year earlier. Chief Executive Ronnie Morris said the company is cautiously optimistic that the pharma and biotech environments are improving. Shares jump 13%, to $6.59, in postmarket trading.

DBV Technologies confirmed alignment with the Food and Drug Administration on an accelerated approval for its Viaskin Peanut Patch in children aged 1 to 3. The biopharmaceutical company said it aligned with the FDA on key study design elements for its Comfort Toddlers study, including study size, wear time collection methodology and analysis. It expects to submit a biologics license application for the toddlers' indication of the Viaskin Peanut Patch in the second half of 2026. Shares surge 28%, to $4.20, in after-hours trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

December 11, 2024 18:40 ET (23:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490812489?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-12 07:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490812489","market":"other","top_or_hot":-1,"title":"Stocks to Watch: Adobe, Champions Oncology, DBV Technologies","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADBE\">Adobe</a>'s fiscal 2025 outlook missed estimates. The software maker expects revenue between $23.3 billion and $23.55 billion for the current fiscal year, missing the $23.78 billion that analysts polled by FactSet expect. It also guided for adjusted per-share earnings between $20.20 and $20.50, compared with the $20.52 for which analysts are looking. The company's lower-than-expected outlook came as it posted higher revenue and earnings in its fiscal 4Q. Shares slide 8.8%, to $501.55, in after-hours trading. \n</p>\n<p>\n  Champions Oncology swung to a profit and reported higher revenue in the latest quarter due to bookings growth and operational improvements. The technology-enabled research company posted earnings of 5 cents a share on revenue of $13.5 million, compared with a loss of 15 cents a share on revenue of $11.6 million a year earlier. Chief Executive Ronnie Morris said the company is cautiously optimistic that the pharma and biotech environments are improving. Shares jump 13%, to $6.59, in postmarket trading. \n</p>\n<p>\n  DBV Technologies confirmed alignment with the Food and Drug Administration on an accelerated approval for its Viaskin Peanut Patch in children aged 1 to 3. The biopharmaceutical company said it aligned with the FDA on key study design elements for its Comfort Toddlers study, including study size, wear time collection methodology and analysis. It expects to submit a biologics license application for the toddlers' indication of the Viaskin Peanut Patch in the second half of 2026. Shares surge 28%, to $4.20, in after-hours trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 11, 2024 18:40 ET (23:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Adobe, Champions Oncology, DBV Technologies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Adobe, Champions Oncology, DBV Technologies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 07:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Connor Hart \n\n\n \n\n\nAdobe's fiscal 2025 outlook missed estimates. The software maker expects revenue between $23.3 billion and $23.55 billion for the current fiscal year, missing the $23.78 billion ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494617.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2490812489","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490812489","pubTimestamp":1733960400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Adobe's fiscal 2025 outlook missed estimates. The software maker expects revenue between $23.3 billion and $23.55 billion for the current fiscal year, missing the $23.78 billion that analysts polled by FactSet expect. It also guided for adjusted per-share earnings between $20.20 and $20.50, compared with the $20.52 for which analysts are looking. The company's lower-than-expected outlook came as it posted higher revenue and earnings in its fiscal 4Q. Shares slide 8.8%, to $501.55, in after-hours trading.Champions Oncology swung to a profit and reported higher revenue in the latest quarter due to bookings growth and operational improvements. The technology-enabled research company posted earnings of 5 cents a share on revenue of $13.5 million, compared with a loss of 15 cents a share on revenue of $11.6 million a year earlier. Chief Executive Ronnie Morris said the company is cautiously optimistic that the pharma and biotech environments are improving. Shares jump 13%, to $6.59, in post","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4528":"SaaS概念","BK4023":"应用软件","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","BK4554":"元宇宙及AR概念","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","LU1815333072.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"AUP\" (USD) INC","BK4585":"ETF&股票定投概念","LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","BK4139":"生物科技","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0557290698.USD":"施罗德环球可持续增长基金","DBV":"Invesco DB G10 Currency Harvest Fund","LU2458330169.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A\" (SGD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2458330243.SGD":"FRANKLIN SHARIAH TECHNOLOGY \"A-H1\" (SGDHDG) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","BK4527":"明星科技股","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","LU0082616367.USD":"摩根大通美国科技A（dist）","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0889565833.HKD":"FRANKLIN TECHNOLOGY \"A\" (HKD) ACC","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","CSBR":"Champions Oncology, Inc.","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0061474960.USD":"天利环球焦点基金AU Acc","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","DBVT":"DBV Technologies S.A.","LU0109392836.USD":"富兰克林科技股A","BK4581":"高盛持仓","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ADBE":"Adobe","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1633808545.USD":"ALLIANZ GLOBAL EQUITY GROWTH \"AT\" (USD) ACC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC"},"translate_title":"值得关注的股票：Adobe、Champions Oncology、DBV Technologies","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADBE":1,"CSBR":1,"DBV":1,"DBVT":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nAdobe's fiscal 2025 outlook missed estimates. The software maker expects revenue between $23.3 billion and $23.55 billion for the current fiscal year, missing the $23.78 billion that analysts polled by FactSet expect. It also guided for adjusted per-share earnings between $20.20 and $20.50, compared with the $20.52 for which analysts are looking. The company's lower-than-expected outlook came as it posted higher revenue and earnings in its fiscal 4Q. Shares slide 8.8%, to $501.55, in after-hours trading. \n\n\n  Champions Oncology swung to a profit and reported higher revenue in the latest quarter due to bookings growth and operational improvements. The technology-enabled research company posted earnings of 5 cents a share on revenue of $13.5 million, compared with a loss of 15 cents a share on revenue of $11.6 million a year earlier. Chief Executive Ronnie Morris said the company is cautiously optimistic that the pharma and biotech environments are improving. Shares jump 13%, to $6.59, in postmarket trading. \n\n\n  DBV Technologies confirmed alignment with the Food and Drug Administration on an accelerated approval for its Viaskin Peanut Patch in children aged 1 to 3. The biopharmaceutical company said it aligned with the FDA on key study design elements for its Comfort Toddlers study, including study size, wear time collection methodology and analysis. It expects to submit a biologics license application for the toddlers' indication of the Viaskin Peanut Patch in the second half of 2026. Shares surge 28%, to $4.20, in after-hours trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 11, 2024 18:40 ET (23:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490812489"}